RENTOKIL METHYL BROMIDE 980 FUMIGANT Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rentokil methyl bromide 980 fumigant

rentokil - methyl bromide(980g/kg)+chloropicrin(20g/kg) - gas (soil fumigant) - group 8a8b insecticide - bed - plant - qps and cue treatment | buildings & similar structures qps & cue | cane products qps & approved cue | cereal grain - damping off - pythium ultimum | damping off - rhizoctonia spp. | damping off fungi | fusarium spp. | insect | nematode - soil borne plant parasitic | nutgrass | rodent, rat or mouse | stored product insect pests | weed seed | black rat/mouse | brown rat/mouse | fat hen | fusarium patch | fusarium spp. | mouse | prince of wales feather | pythium spp. | rat | rhizoctonia spp. | rodent | roof rat | soil fungi | victorian nutgrass | weed seeds | winter grass

NUFARM METHYL BROMIDE 1000 FUMIGANT Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm methyl bromide 1000 fumigant

nufarm - methyl bromide(1000g/kg) - liquid - group 8a insecticide - bed - plant - qps and cue treatment | buildings & similar structures qps & cue | cane products qps & approved cue | cereal grain - brown rot - sclerotinia spp. | crown rot - verticillium spp. | damping off - pythium ultimum | damping off - rhizoctonia spp. | damping off fungi | fusarium spp. | insect | nematode - soil borne plant parasitic | nutgrass | rodent, rat or mouse | stored product insect pests | weed seed | black rat/mouse | blossom blight | brown rat/mouse | fat hen | fusarium patch | fusarium spp. | mouse | prince of wales feather | pythium spp. | rat | rhizoctonia spp. | rodent | roof rat | soil fungi | victorian nutgrass | weed seeds | winter grass

AGRIGAS M METHYL BROMIDE FUMIGANT Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agrigas m methyl bromide fumigant

boc limited - methyl bromide - gas (soil fumigant) - methyl bromide gas active 1000.0 g/kg - mixed function pesticide - buildings & similar structures qps & cue | cane products qps & approved cue | cereal grain qps & approved cue | chocolate qps & - rodent, rat or mouse | stored product insect pests | black rat/mouse | brown rat/mouse | mouse | rat | rodent | roof rat

Brima-Fume Methyl Bromide New Zealand - English - Ministry for Primary Industries

brima-fume methyl bromide

leicester's new zealand limited - methyl bromide - methyl bromide 1,000 g/kg - insecticide

METHYL BROMIDE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

methyl bromide

trical australia pty ltd - methyl bromide - unknown - methyl bromide gas active 0.0 - active constituent

SA RURAL METHYL BROMIDE 980 FUMIGANT Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sa rural methyl bromide 980 fumigant

trical australia pty ltd - chloropicrin; methyl bromide - gas (soil fumigant) - chloropicrin gas active 20.0 g/kg; methyl bromide gas active 980.0 g/kg - mixed function pesticide - bed - plant - qps and cue treatment | buildings & similar structures qps & cue | cane products qps & approved cue | cereal grain - damping off - pythium ultimum | damping off - rhizoctonia spp. | damping off fungi | fusarium spp. | insect | nematode - soil borne plant parasitic | nutgrass | rodent, rat or mouse | stored product insect pests | weed seed | black rat/mouse | brown rat/mouse | fat hen | fusarium patch | fusarium spp. | mouse | prince of wales feather | pythium spp. | rat | rhizoctonia spp. | rodent | roof rat | soil fungi | victorian nutgrass | weed seeds | winter grass

METHYLPHENIDATE HYDROCHLORIDE tablet, extended release United States - English - NLM (National Library of Medicine)

methylphenidate hydrochloride tablet, extended release

lannett company, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 18 mg - methylphenidate hcl extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see clinical studies (14)] . a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; e

METHYLPHENIDATE HYDROCHLORIDE (LA)- methylphenidate hydrochloride capsule, extended release United States - English - NLM (National Library of Medicine)

methylphenidate hydrochloride (la)- methylphenidate hydrochloride capsule, extended release

mayne pharma - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 20 mg - methylphenidate hydrochloride extended-release capsules (la) are indicated for the treatment of attention deficit hyperactivity disorder (adhd). the efficacy of methylphenidate hydrochloride extended-release capsules (la) in the treatment of adhd was established in 1 controlled trial of children aged 6 to 12 who met dsm-iv criteria for adhd (see clinical pharmacology). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor

METHYLPHENIDATE HYDROCHLORIDE (LA)- methylphenidate hydrochloride capsule, extended release United States - English - NLM (National Library of Medicine)

methylphenidate hydrochloride (la)- methylphenidate hydrochloride capsule, extended release

teva pharmaceuticals usa, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 20 mg - methylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd), in pediatric patients 6 to 12 years of age [see clinical studies (14)] . - hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride extended-release capsules. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [ s ee adverse reactions (6.1)]. - concomitant treatment with monoamine oxidase inhibitors (maois), or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [ see drug interactions (7.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including methylphenidate hydrochloride extended-release capsules during pregnancy. healthcare providers are encouraged to register patients by calling the national pregna

METHYLPHENIDATE HYDROCHLORIDE tablet
METHYLPHENIDATE HYDROCHLORIDE tablet, extended release United States - English - NLM (National Library of Medicine)

methylphenidate hydrochloride tablet methylphenidate hydrochloride tablet, extended release

specgx llc - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - methylphenidate hydrochloride tablets and methylphenidate hydrochloride extended-release tablets are indicated for the treatment of: - attention deficit hyperactivity disorders (adhd) in pediatric patients 6 years and older and adults - narcolepsy - hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride tablets or methylphenidate hydrochloride extended-release tablets. hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate [see adverse reactions (6)] . - concomitant treatment with monoamine oxidase inhibitors (maois), or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [see drug interactions (7.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including methylphenidate hydrochloride tablets and methylphenidate hydrochloride extended-release